Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes
Open Access
- 1 January 2005
- journal article
- review article
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 81 (951) , 1-6
- https://doi.org/10.1136/pgmj.2004.020511
Abstract
The worldwide prevalence of type 2 diabetes mellitus has reached epidemic proportions. The so-called traditional risk factors cannot fully explain the excessive cardiovascular disease risk of type 2 diabetic patients. Numerous studies indicate that postprandial metabolic derangements, most notably hyperglycaemia and hypertriglyceridaemia, which are exaggerated and prolonged in type 2 diabetes, are important cardiovascular disease risk factors since they induce oxidative stress and endothelial dysfunctions. This review discusses the current evidence showing that postprandial dysmetabolism may indeed constitute an important cardiovascular disease risk factor as well as the mechanisms underlying this association. Finally, some possible therapeutic options and recommendations for future research are discussed.Keywords
This publication has 67 references indexed in Scilit:
- Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetesDiabetes/Metabolism Research and Reviews, 2002
- Inflammatory Cytokine Concentrations Are Acutely Increased by Hyperglycemia in HumansCirculation, 2002
- Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes.Diabetes Care, 2000
- The Importance of Hyperglycemia in the Nonfasting State to the Development of Cardiovascular DiseaseEndocrine Reviews, 1998
- Increased PAI activity and PAI-1 antigen occurring with an oral fat load: associations with PAI-1 genotype and plasma active TGF-β levelsAtherosclerosis, 1998
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Pramlintide, a Synthetic Analog of Human Amylin, Improves the Metabolic Profile of Patients With Type 2 Diabetes Using InsulinDiabetes Care, 1998
- Effect of Metformin on Postprandial Lipemia in Patients With Fairly to Poorly Controlled NIDDMDiabetes Care, 1994
- The Effect of Insulin Treatment on HbA1c, Body Weight and Lipids in Type 2 Diabetic Patients with Secondary-Failure to Sulfonylureas.Hormone and Metabolic Research, 1992
- Atherogenesis: a postprandial phenomenon.Circulation, 1979